Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V114 in healthy infants in South Korea
2020-003181-39Phase 3
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 15-valent conjugate vaccine in pneumococcal disease, sponsored by Merck & Co. Primary endpoint: Percentage of participants with ≥1 solicited injection-site adverse events.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2020-003181-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003181-39.